March 30, 2017
Weil was highlighted as antitrust counsel to Allergan in the divestiture of its global generic pharmaceutical business to Teva Pharmaceuticals, which was named “Merger Control Matter of the Year” for the Americas by Global Competition Review. The transaction, valued at approximately $39 billion, was completed in August 2016. Weil’s Antitrust team advising Allergan was led by partner and Head of Weil’s global Antitrust/Competition practice Steven Newborn, and included partners Ann Malester and Jeff White, and associate Daniel Antalics.
The seventh annual GCR Awards were held on March 28 in Washington, D.C. and celebrated the best in competition enforcement, merger and cartel defense, and overall achievement.